Krystal®

Third Quarter 2024
Financial Results and Business Update

November 4, 2024

Forward Looking Statements and Disclosures

This presentation, which includes the accompanying oral presentation, contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotech, Inc. (together with its subsidiaries and affiliates, the "Company"), including but not limited to statements about the Company's beliefs regarding significant potential for value creation driven both by VYJUVEK and its deep clinical-stage pipeline and its expectations of significant revenue growth in the coming years; the Company's U.S. commercial launch of VYJUVEK, including its expectations regarding sustaining the launch, meeting its pre-launch penetration target and meeting and exceeding other targets, patient compliance with weekly treatments, and the impact of its use of social media; the Company's expectations and beliefs regarding its efforts to bring B-VEC to market in Europe and Japan, including expected timing of filings, marketing approvals, labeling, and commercial launches; the Company's expectations regarding the benefits of France's approval of pre-marketing early reimbursed access for B-VEC under the AP1 program and the timing of patient access to B-VEC under that program; the Company's beliefs about the potential of KB301 in the field of regenerative aesthetics and its plans to progress KB301 to a Phase 2 study in 2025; the Company's plans to disclose data readouts from clinical studies of certain of its pipeline products by the end of 2024, which the Company expects will showcase the breadth and potential of its HSV-1 based gene delivery platform technology, including gene delivery to the lung; the Company's plans, expectations, and timing regarding data updates for KB707 and KB407 in 2025; the Company's plans to commence its registrational trial to evaluate its ophthalmic formulation of B-VEC and its expectations of the benefits of the ongoing natural history study; estimated financial measures, including the Company's 2024 non-GAAP combined R&D and SG&A expense guidance; and other statements containing the words "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "predict", "project", "target", "potential", "likely", "will", "would", "could", "should", "continue" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties associated with regulatory review of manufacturing processes and clinical trials and the content and timing of decisions made by regulatory authorities; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials and utility of such data; uncertainties associated with manufacturing and availability or commercial potential of products; and such other important factors as are set forth in the Company's filings with the U.S. Securities and Exchange Commission. The forward-looking statements included in this presentation represent the Company's views as of the date of this presentation and should not be relied upon as representing the Company's views as of any subsequent date.

This presentation includes non-GAAP combined R&D and SG&A expense guidance, a supplemental measure of the Company's performance that is not required by, or presented in accordance with, U.S. GAAP and should not be considered as an alternative to R&D and SG&A expense or any other performance measure derived in accordance with GAAP. The Company defines non-GAAP combined R&D and SG&A expense as GAAP combined R&D and SG&A expense excluding stock-based compensation. The Company cautions investors that amounts presented in accordance with its definition of non-GAAP combined R&D and SG&A expense may not be comparable to similar measures disclosed by other companies because not all companies calculate this non-GAAP financial measure in the same manner. The Company has not provided a quantitative reconciliation of forecasted non-GAAP combined R&D and SG&A expense to forecasted GAAP combined R&D and SG&A expense because the Company is unable, without making unreasonable efforts, to calculate the reconciling item, stock-based compensation expenses, with confidence. This item, which could materially affect the computation of forward-looking GAAP combined R&D and SG&A expense, is inherently uncertain and depends on various factors, some of which are outside of the Company's control.

This presentation may contain estimates and statistical data. These estimates involve assumptions and limitations, and investors are cautioned not to give undue weight to such estimates. Neither the Company nor any other person makes any representation as to the accuracy or completeness of such estimates or data or undertakes any obligation to update such estimates or data. Any projections, assumptions and estimates of the Company's future performance and the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk.

Other than VYJUVEK, all products described in this presentation are investigational therapies.

The Company is using the Aerogen Solo® Nebulizer System and Aerogen® Ultra in its clinical trials evaluating KB407, KB408, and inhaled KB707.

3Q 2024 Highlights

- VYJUVEK launch momentum continues in 3Q 2024
  - CHMP opinion anticipated in 4Q 2024 and on track to launch in Europe in 1H 2025
  - French authorities approved pre-marketing early reimbursed access for B-VEC in France
  - JNDA filed in Japan and on track to launch in Japan in 2H 2025
- Two clinical readouts upcoming before year end
  - Jeune Aesthetics' reported positive Phase 1 results in décolleté and lateral canthal lines
- Strong balance sheet bolstered by another profitable quarter

CHMP, Committee for Medicinal Products for Human Use; JNDA, Japan New Drug Application

Over $250M in Net Revenue Since VYJUVEK Launch in August 2023



Vyjuvek®
beremagene geperpavec-svdt

- Net revenue includes accrual for subset of U.S. patients on commercial insurance estimated to hit payment caps in 2024
- Gross margin of 92% in 3Q | Gross to net in 3Q was 17%

Over 460 Reimbursement Approvals as of October 2024

Reimbursement Approvals Breakdown



Percentages may not total 100% due to rounding

VYJUVEK Site of Care



All reauthorization requests either approved or in process
97% of covered lives under commercial and Medicaid plans with positive access
Patient drug utilization/compliance while on drug = 87%

Reimbursement approval and site of care metrics as of October 2024, compliance through 3Q 2024

Tracking Towards Our Ambitious Two Year Penetration Target in US



Filing Submitted in Japan, On Track for Launches in Europe and Japan in 2025

Europe

- ✓ **MAA validated by EMA in November 2023**
- ✓ **EU-GMP certification received May 2024**
- ✓ **Pre-marketing early reimbursed access for B-VEC approved in France under Accès Précoce (AP1) in September 2024**
- ❑ AP1 program expected to start before end of year
- ❑ CHMP opinion expected by end of year
- ❑ On track for EMA decision and first ex-U.S. launch in Germany in 1H 2025

Japan

- ✓ **ODD received in December 2023**
- ✓ **JNDA submitted in October 2024**
- ❑ Decision and launch expected 2H 2025

Filings in both major ex-U.S. markets are under review

CHMP, Committee for Medicinal Products for Human Use; EMA, European Medicines Agency; EU, European Union; GMP, good manufacturing practices; JNDA, Japan New Drug Application; ODD, Orphan Drug Designation

Clinical Readouts This Year and Continuing into 2025

Two more clinical readouts before end of year

- ❑ KB408 for alpha-1 antitrypsin deficiency lung disease
- ❑ KB707 for solid tumors



✓ Positive readout for KB301 in treatment of aesthetic indications

- Reported positive safety and efficacy data in two Phase 1 cohorts evaluating KB301 in the lateral canthal region and the décolleté
- Clear and clinically significant improvements reported for wrinkles and multiple other skin attributes including radiance, hydration, and crepiness
- Décolleté indication selected for Phase 2 study expected to start in **2025**

JEUNE

At least three additional readouts in 2025

- ❑ Ophthalmic B-VEC for ocular DEB complications
- ❑ KB407 for cystic fibrosis
- ❑ Additional updates on KB707 for solid tumors

B-VEC, beremagene geperpavec; DEB, dystrophic epidermolysis bullosa

Third Quarter 2024 Financial Highlights

Cash and investments: $694.2 million as of September 30, 2024

($ in millions; except per share data)	Three Months Ended September 30	
	2024	2023
Product revenue, net	$83.8	$8.6
Cost of goods sold	$6.7	$0.2
R&D expenses	$13.5	$10.6
SG&A expenses	$28.7	$23.7
Gain from sale of priority review voucher	—	$100.0
Stock-based compensation expense	$13.3	$8.3
Net income	$27.2	$80.7
Net income per share (basic)	$0.95	$2.88
Net income per share (diluted)	$0.91	$2.79

Non-GAAP R&D and SG&A Expense Guidance for Full Year 2024 expectation updated to **$115M to $125M***

GAAP, generally accepted accounting principles; R&D, research and development; SG&A, selling, general, and administrative expenses

*Non-GAAP combined R&D and SG&A Expense guidance does not include stock-based compensation as we are currently unable to confidently estimate Full Year 2024 stock-based compensation expense. As such, we have not provided a reconciliation from forecasted non-GAAP to forecasted GAAP combined R&D and SG&A Expense in the above. This could materially affect the calculation of forward-looking GAAP combined R&D and SG&A Expenses, as it is inherently uncertain.

Building Out a Portfolio of Redosable Genetic Medicines

		Indication	Payload	Preclinical	Phase 1/2	Phase 3	Commercial
Vyjuvek® beremagene geperpavec-svdt 5x10⁹ PFU/mL single-use vial		Dystrophic epidermolysis bullosa	*COL7A1*		**FDA Approved May 2023**		Marketed in the U.S.
Dermatology	**KB105**	Lamellar ichthyosis	*TGM1*			**1H 2025 Ph 2 Start**	
	KB104	Netherton syndrome	*SPINK5*				
	Additional program(s) targeting dermatology indications						
Respiratory	**KB407**	Cystic fibrosis	*CFTR*			**1H 2025 Ph 1 Interim Data**	
	KB408	Alpha-1 antitrypsin deficiency (AATD)	*SERPINA1*			**4Q 2024 Ph 1 Interim Data**	
	Additional program(s) targeting respiratory indications						
Oncology	**Injectable KB707**	Solid tumors including cutaneous	*IL2 + IL12*			**4Q 2024 Ph 1 Interim Data**	
	Inhaled KB707	Solid tumors of the lung	*IL2 + IL12*				
Ophthalmology	**Ophthalmic B-VEC**	Ocular complications of DEB	*COL7A1*			**1H 2025 Ph 3 Start**	
	Program(s) targeting ophthalmology indications						

+ Wholly-Owned Clinical-Stage Aesthetics Subsidiary

JEUNE

2025 Ph 2 Start

B-VEC, beremagene geperpavec; CFTR, cystic fibrosis transmembrane conductance regulator; COL7A1, collagen type VII alpha 1 chain; DEB, dystrophic epidermolysis bullosa; FDA, US Food and Drug Administration; IL-12, interleukin-12; IL-2, interleukin-2; SERPINA1, serpin family A member 1; SPINK5, serine protease inhibitor Kazal-type 5; TGM1, transglutaminase-1; U.S., United States

Other than VYJUVEK, all products described in this presentation are investigational therapies

Krystal®

Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs